EGFR and breast cancer: We show that somatic mutations frequently observed in breast cancer lead to β-catenin activation: this observation strengthens emerging data outlining the relevance of the β-catenin activation in breast cancer [44], [45] and the crosstalk between EGFR and WNT signals in breast cancer development [46].